RedFlag Index™ · #10 of 10 · NYSE: MRK

Merck & Co., Inc.: enforcement record and regulatory exposure

Merck & Co., Inc. scores 36 out of 100 on the RedFlag Index™ (October 2026), ranking #10 of ten tracked companies, with 3 documented cases of which 1 remain open.

Merck has paid more than $10.7 billion in tracked penalties since 2000.

2011–2012: Merck paid $950 million and pleaded guilty to illegally promoting Vioxx, including a $321.6 million criminal fine.

2008: Merck paid $650 million over pricing and kickback allegations involving Zocor, Vioxx, and Pepcid.

  1. Off-Label Promotion

    Merck's Vioxx penalty was $950 million. It arrived eight years after the drug was pulled.

    Merck pleaded guilty to a misdemeanor. It did not admit the civil allegations about cardiovascular safety.

  2. Drug Pricing

    Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation

    Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.